This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Tel Aviv University, Other. Active years: 2013-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 843 
1 out of 834,570 Years Active: 2013-2015
Title: Naama David - Innovator in Targeted Cancer Therapy
Introduction
Naama David is a notable inventor based in Givatayim, Israel. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches to targeted treatments. With a total of 2 patents, his work focuses on utilizing microRNA for therapeutic purposes.
Latest Patents
David's latest patents include the MIR-21 promoter driven targeted cancer therapy. This invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, such as a toxin. The constructs of this invention are particularly useful for treating tumors that express miR-21.
Career Highlights
Throughout his career, Naama David has worked with prestigious institutions, including Tel Aviv University. His research has been pivotal in advancing the understanding and treatment of cancer through innovative methodologies.
Collaborations
Some of his notable coworkers include Alona Zilberberg and Rina Rosin-Arbesfeld, who have contributed to his research endeavors.
Conclusion
Naama David's work in targeted cancer therapy exemplifies the impact of innovative thinking in medicine. His contributions continue to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile